Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.

Kenichiro HataTakuya KotaniShogo MatsudaYouhei FujikiTakayasu SuzukaTakao KiboshiYumiko WadaHideyuki ShibaTakeshi ShodaMaki KagitaniTohru Takeuchi

Published in: International journal of rheumatic diseases (2023)

This aggressive multi-combination therapy may improve the survival outcome of patients with anti-MDA5 antibody-positive DM-RPILD. However, careful management of complications, such as opportunistic infections and leukopenia, is essential. Future refinement through longitudinal investigations tracking the long-term efficacy, safety, and cost-effectiveness of this treatment strategy is needed.

Keyphrases

combination therapy
interstitial lung disease
systemic sclerosis
rheumatoid arthritis
idiopathic pulmonary fibrosis
breast cancer cells
multiple sclerosis
risk factors
cross sectional
cell cycle arrest
current status
metabolic syndrome
cell death
signaling pathway
adipose tissue
glycemic control